Position in NGEN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$0
New position
Shares Held
0
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2026
1 quarter on record
Derivatives in NGEN
reported options exposure · as of Jun 30, 2026CallValue
$57,268
CallShares
27,800
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026CITADEL ADVISORS LLC holds $6,088,670,159 across 436 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ONC |
BeOne Medicines Ltd.
|
1,425,517 | $406,229,578 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
3,760,028 | $280,046,885 | |
| 3 | INSM |
INSMED Inc
|
2,556,973 | $272,624,460 | |
| 4 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
507,233 | $272,358,759 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
510,430 | $253,545,893 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
1,006,676 | $242,578,715 | |
| 7 | MANE |
Veradermics, Inc
|
1,877,775 | $230,853,658 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
5,576,261 | $197,343,876 |
All Filings in NGEN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $57,268 | 27,800 | Call | Defined | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||